GlassScriptPhysician profile
Jacob Jorns
NPI 1871737064
$4,276.95
in general payments reported to CMS, 2019-2025
34 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $50.64 · 2021: $157 · 2022: $570 · 2023: $771 · 2024: $1,041 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $732.28 | 2019-2025 | Tria Firm, General - Kidney Stone Disease, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $625.00 | 2019-2023 | Xtandi |
| Abbvie INC. | $614.17 | 2022-2025 | |
| Janssen Biotech, INC. | $310.73 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Urogen Pharma, INC. | $222.30 | 2024-2025 | |
| Procept Biorobotics Corporation | $200.53 | 2022-2024 | Aquabeam System, Aquabeam Robotic System |
| Urovant Sciences INC | $174.42 | 2022 | |
| Olympus America INC. | $160.80 | 2023-2024 | Itind System, Soltive |
| Sumitomo Pharma America, INC. | $131.19 | 2023-2025 | Gemtesa, Orgovyx |
| Endo USA, INC. | $127.14 | 2024-2025 | Xiaflex, Aveed |
| Pfizer INC. | $117.53 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $91.89 | 2024 | Magnetom Vida |
| Endo Pharmaceuticals INC. | $83.15 | 2019-2024 | Xiaflex, Aveed, Edex |
| Coloplast Corp | $77.97 | 2022-2023 | Porges Coloplast |
| Medtronic, INC. | $72.85 | 2023-2025 | Interstim, Nuro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $65.40 | 2025 | Adstiladrin |
| C. R. Bard, INC. & Subsidiaries | $58.65 | 2019 | |
| Antares Pharma, INC. | $53.24 | 2024-2025 | Xyosted |
| Allergan, INC. | $49.94 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $43.55 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $37.30 | 2025 | |
| Immunitybio, INC. | $34.39 | 2025 | |
| Blue Earth Diagnostics | $26.52 | 2024 | |
| Myriad Genetic Laboratories, INC. | $21.78 | 2025 | Prolaris |
| Myovant Sciences INC. | $21.74 | 2022 | |
| Axonics, INC. | $20.36 | 2023 | Axonics |
| Photocure INC | $19.58 | 2024 | Cysview |
| Dendreon Pharmaceuticals LLC | $16.61 | 2025 | Provenge |
| Ambu INC. | $13.52 | 2025 | |
| Profound Medical Corp. | $13.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.12 | 2019 | |
| Abc Home Medical Supply, INC. | $13.09 | 2022 | |
| Amgen INC. | $13.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Jorns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.